The effects of azathioprine and 6 MP on immunity
- PMID: 401430
- DOI: 10.3109/08923977909040545
The effects of azathioprine and 6 MP on immunity
Abstract
The thiopurines, azathioprine and 6 MP are potent inhibitors of both experimental and clinical immune responses. The primary pharmacological activities are mediated by competitive inhibition of enzymes concerned with de novo purine base synthesis; Immunosuppressive activities appear to result from cytotoxic activities directed against antigen-responsive lymphocytes; this inhibition is maximal when the treatment course coincides with the proliferative expansion phase of the response. By contrast, thiopurines are comparatively ineffective if used during an effector phase of an immune response. Furthermore, administration prior to antigenic challenge does not lead to immune inhibition; in fact, it may lead to augmentation of selected immune responses. Treatment with thiopurines does not result in acute lymphopenia; prolonged courses will cause a moderate decrease in circulating lymphocytes. The drug does not selectively deplete peripheral T or B cells but can acutely reduce K (killer) cells, which are effectors in ADCC responses. In addition, short-lived thymocytes and marrow lymphocytes are rapidly depleted by these anti-metabolites. Many in vitro functions of lymphocytes, from treated animals remain normal. Recent studies indicate that, in vitro, azathioprine is specifically able to bind murine T lymphocytes; this can be shown by their ability to inhibit their capacity to rosette with sheep erythrocytes. Azathioprine is also a potent inhibitor of mixed lymphocyte culture responses and can readily suppress the in vitro generation of cytotoxic T cells. These observations suggest that drugs exert preferential toxicities for murine T cells. B lymphocytes for mice appear to vary in their susceptibility for thiopurines. By contrast, the activity of human B cells can be readily suppressed with this drug whereas T helper function is comparatively resistant. In addition to immunosuppressive properties, thiopurines are capable of exerting anti-inflammatory activities, primarily by inhibiting the replication of hematopoietic precursors.
Similar articles
-
Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines.J Pharmacol Exp Ther. 2005 Feb;312(2):537-45. doi: 10.1124/jpet.104.074815. Epub 2004 Sep 23. J Pharmacol Exp Ther. 2005. PMID: 15388785
-
Azathioprine suppresses the mixed lymphocyte reaction of patients with Lesch-Nyhan syndrome.Br J Clin Pharmacol. 1985 Nov;20(5):489-91. doi: 10.1111/j.1365-2125.1985.tb05104.x. Br J Clin Pharmacol. 1985. PMID: 2934083 Free PMC article.
-
Azathioprine and 6-mercaptopurine (6-MP) suppress the human mixed lymphocyte reaction (MLR) by different mechanisms.Br J Clin Pharmacol. 1984 Apr;17(4):417-22. doi: 10.1111/j.1365-2125.1984.tb02366.x. Br J Clin Pharmacol. 1984. PMID: 6232936 Free PMC article.
-
Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine.Aliment Pharmacol Ther. 2001 Nov;15(11):1699-708. doi: 10.1046/j.1365-2036.2001.01102.x. Aliment Pharmacol Ther. 2001. PMID: 11683683 Review.
-
Thiopurines in Inflammatory Bowel Disease: New Findings and Perspectives.J Crohns Colitis. 2018 Apr 27;12(5):610-620. doi: 10.1093/ecco-jcc/jjx181. J Crohns Colitis. 2018. PMID: 29293971 Review.
Cited by
-
SARS-CoV-2-associated warm autoimmune haemolytic anaemia in an immunosuppressed patient: The trend continues.Transfus Med. 2022 Dec;32(6):525-526. doi: 10.1111/tme.12928. Epub 2022 Oct 17. Transfus Med. 2022. PMID: 36251668 Free PMC article. No abstract available.
-
Murine B-lymphocyte colony formation: the effects of cyclophosphamide and azathioprine.Immunology. 1982 Aug;46(4):827-32. Immunology. 1982. PMID: 6980824 Free PMC article.
-
The use of therapeutic drug monitoring to optimise immunosuppressive therapy.Clin Pharmacokinet. 1996 Feb;30(2):107-40. doi: 10.2165/00003088-199630020-00003. Clin Pharmacokinet. 1996. PMID: 8906895 Review.
-
Patient ancestry significantly contributes to molecular heterogeneity of systemic lupus erythematosus.JCI Insight. 2020 Aug 6;5(15):e140380. doi: 10.1172/jci.insight.140380. JCI Insight. 2020. PMID: 32759501 Free PMC article.
-
Immunomodulator therapy in inflammatory bowel disease.Dig Dis Sci. 1994 Sep;39(9):1885-92. doi: 10.1007/BF02088121. Dig Dis Sci. 1994. PMID: 7521821 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources